Restoring Vision. Transforming Lives.
200M patients suffer from Age-related Macular Degeneration (AMD). It is the leading cause of visual impairment and blindness in the world and can happen to anyone. AMD can reduce a patient's quality of life up to 60%, a burden similar to that of advanced cancer or a major stroke. Currently there is no treatment available.
Miriditas is developing the first safe and effective treatment against AMD
About Us
We are a biotechnology company located in The Netherlands developing promising small molecule based therapies.
Miriditas focuses on safe, effective therapies for chronic inflammatory diseases. Our first candidate, MIR001, offers hope to millions of patients with AMD worldwide.
Impact
Dry AMD characterized by a blurry vision, which can't be restored with glasses and precedes the wet form of the disease.
Wet AMD
characterized by a large spot of total vision loss, becoming increasingly larger.
Burden
200M diagnosed patients: 180M with dry AMD and 20M with wet AMD.
Opportunity
No effective treatments available for dry AMD. Monthly injections with anti-VEGF antibodies is the Standard of Care for wet AMD (treatment only stops progression rate)